Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRL 201104

Next Previous
Drug Profile

IRL 201104

Alternative Names: '1104; ILR 201104; IRL1104; IRL201104; PIN-201104

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kings College London; Peptinnovate; St. Georges University of London
  • Developer Revolo Biotherapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic oesophagitis; Seasonal allergic rhinitis
  • Preclinical Adult respiratory distress syndrome
  • No development reported Asthma

Most Recent Events

  • 30 Jan 2024 IRL 201104 receives Orphan Drug status for Eosinophilic oesophagitis in USA
  • 30 Jan 2024 Revolo Biotherapeutics plans a phase IIb trial for Eosinophilic oesophagitis (In adults) (IV), in 2024
  • 25 Oct 2023 Efficacy and safety data from a phase IIa trial in Seasonal allergic rhinitis released by Revolo Biotherapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top